Anti-Hu CD79b APC

Anti-Hu CD79b APC
Regulatory status
RUO
Antigen
CD79b
Clone
CB3-1
Format
APC
Reactivity
Human
Application
Excitation laser
red (633 nm)
Variant
100 tests
1A-676-T100
In stock
242.00 USD

25 tests
1A-676-T025
Delivery 1 week
121.00 USD
Variant
100 tests
1A-676-T100
In stock
242.00 USD

25 tests
1A-676-T025
Delivery 1 week
121.00 USD
Product details
Description
Images
References
SDS download
Isotype
Mouse IgG1 kappa
Specificity
The mouse monoclonal antibody CB3-1 recognizes an extracellular epitope of CD79b (CD79 beta, Ig beta), an approximately 38 kDa component of B cell receptor (BCR) complex.
Workshop
HLDA VI: WS Code CD79.1
Application
Application details
Flow cytometry: The reagent is designed for analysis of human blood cells using 10 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
Reactivity
Human
Immunogen
Fraction of Ig-associated molecules isolated from Ramos B cells
Preparation
Purified antibody is conjugated with activated allophycocyanin (APC) under optimum conditions and unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
Formulation
Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Other names
BCR beta, Ig-beta, B29, IGB
Antigen description
CD79b (Ig beta, B29) forms disulfide-linked heterodimer with CD79a (Ig alpha, MB1). They both are transmembrane proteins with extended cytoplasmic domains containing immunoreceptor tyrosine activation motives (ITAMs), and together with cell surface immunoglobulin they constitute B-cell antigen-specific receptor (BCR). CD79a and b are the first components of BCR that are expressed developmentally. They appear on pro-B cells in association with the endoplasmic reticulum chaperone calnexin. Subsequently, in pre-B cells, CD79 heterodimer is associated with lambda5-VpreB surrogate immunoglobulin and later with antigen-specific surface immunoglobulins. CD79a/b complex interacts with Src-family tyrosine kinase Lyn, which phosphorylates its cytoplasmic ITAM motives to form docking sites for downstream signaling.
Entrez Gene ID 974
UniProt ID P40259
1A-676 FC
Flow cytometry analysis (surface staining) of CD79b in human peripheral blood with anti-CD79b (CB3-1) APC.

Product specific references:

Nakamura T, Kubagawa H, Cooper MD: Heterogeneity of immunoglobulin-associated molecules on human B cells identified by monoclonal antibodies. Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8522-6.
PubMed
Zheng B, Fuji RN, Elkins K, Yu SF, Fuh FK, Chuh J, Tan C, Hongo JA, Raab H, Kozak KR, Williams M, McDorman E, Eaton D, Ebens A, Polson AG: In vivo effects of targeting CD79b with antibodies and antibody-drug conjugates. Mol Cancer Ther. 2009 Oct;8(10):2937-46.
PubMed
Garcia Vela J, Delgado I, Benito L, Monteserin M, Garcia Alonso L, Somolinos N, Andreu M, Oña F: CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection. Leukemia. 1999 Oct;13(10):1501-5.
PubMed
Rassenti LZ, Kipps TJ: Expression of Ig-beta (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. Blood. 2000 Apr 15;95(8):2725-7.
PubMed
Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, French D, Go MA, Jack A, Junutula JR, Koeppen H, Lau J, McBride J, Rawstron A, Shi X, Yu N, Yu SF, Yue P, Zheng B, Ebens A, Polson AG: Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009 Sep 24;114(13):2721-9.
PubMed
Matutes E: New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders. J Clin Pathol. 2002 Mar;55(3):180-3.
PubMed
D'Arena G, Cascavilla N, Musto P, Colella Bisogno R, Pistolese G, Carotenuto M: CD79b expression in B-cell chronic lymphocytic leukemia. Haematologica. 2000 May;85(5):556-7.
PubMed
Variant
100 tests
1A-676-T100
In stock
242.00 USD

25 tests
1A-676-T025
Delivery 1 week
121.00 USD
Variant
100 tests
1A-676-T100
In stock
242.00 USD

25 tests
1A-676-T025
Delivery 1 week
121.00 USD

Related products

-134%
Reg. statusCE IVD
ApplicationFC
100 ml
220.00 USD
-134%
Reg. statusCE IVD
ApplicationFC
100 ml
66.00 USD
-134%
Reg. statusRUO
ApplicationFC
100 ml
55.00 USD
-134%
CloneMOPC-21
Reg. statusRUO
ApplicationFC, FC(IC)
0.1 mg
198.00 USD